Cemiplimab vs Retifanlimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Cemiplimab
Marketed by Regeneron Pharmaceuticals and partners
NCT03088540 · Phase 3 · completed
This was a large, randomized, actively-controlled trial with two hard clinical endpoints, survival and progression-free survival, both of which showed a statistically significant benefit for cemiplimab (median overall survival 23.4 vs 13.7 months; progression-free survival assessed by an independent, blinded reviewer). However, patients and treating doctors knew which treatment was being given, since the study was not blinded, which is a real limitation despite the otherwise strong design and the clear-cut result.
Next expected readout: December 2026 · NCT06623656 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to 94 months); Progression-free Survival (PFS) Per Blinded IRC (Up to 94 months): Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) (met)
Result source: NCT03088540
Retifanlimab
Marketed by Incyte
NCT04205812 · Phase 3 · completed
Participants were randomly assigned and double-blinded to receive retifanlimab or placebo with standard chemotherapy, with 391 in the retifanlimab group and 192 in the control group. The hard clinical primary endpoint of overall survival was met, favoring retifanlimab (hazard ratio 0.75; p=0.0042).
Next expected readout: December 2027 · NCT07219576 (registry estimate)
Reported efficacy
Overall Survival (up to 39.1 months): Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) (met)
Result source: NCT04205812
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cemiplimab | Retifanlimab |
|---|---|---|
| PFS, median | 6.3 vs 5.3vs ChemotherapyNCT030885403 other results
| 7.7 vs 5.5+2.2 vs placeboNCT04205812 |
| OS, median | 21.1 vs 12.9+8.2 vs placeboNCT034096143 other results
| 18.1 vs 13.4+4.7 vs placeboNCT04205812 |
| ORR | 43.6% vs 22.1%+21.5 vs placeboNCT034096143 other results
| 51.7% vs 38.5%+13.2 vs placeboNCT04205812 |
| Duration of response, median | 16.4 vs 7.3+9.1 vs placeboNCT034096143 other results
| 12.7 vs 6.1+6.6 vs placeboNCT04205812 |
PFS, median
- Cemiplimab
- 6.3 vs 5.3vs ChemotherapyNCT03088540
3 other results
- 8.2 vs 5.5 NCT03409614
- 6.5 vs 6.4 NCT03409614
- 6.4 vs 6.4 NCT03409614
- Retifanlimab
- 7.7 vs 5.5+2.2 vs placeboNCT04205812
OS, median
- Cemiplimab
- 21.1 vs 12.9+8.2 vs placeboNCT03409614
3 other results
- 23.4 vs 13.7 NCT03088540
- 15.9 vs 13.9 NCT03409614
- 20.1 vs 13.9 NCT03409614
- Retifanlimab
- 18.1 vs 13.4+4.7 vs placeboNCT04205812
ORR
- Cemiplimab
- 43.6% vs 22.1%+21.5 vs placeboNCT03409614
3 other results
- 42.3% vs 21.4% NCT03088540
- 40.7% vs 28.3% NCT03409614
- 36.7% vs 28.3% NCT03409614
- Retifanlimab
- 51.7% vs 38.5%+13.2 vs placeboNCT04205812
Duration of response, median
- Cemiplimab
- 16.4 vs 7.3+9.1 vs placeboNCT03409614
3 other results
- 24.1 vs 5.9 NCT03088540
- 7.8 vs 6.2 NCT03409614
- 15.9 vs 6.2 NCT03409614
- Retifanlimab
- 12.7 vs 6.1+6.6 vs placeboNCT04205812
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Cemiplimab: 4 of 4 rows · Retifanlimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cemiplimab | Retifanlimab |
|---|---|---|
| Dropout rate | 79%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 90.7%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 91.7%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 90.1%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 0%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 0%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | 100%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Discontinued due to AEs | 0.3%Cemiplimaba NCT03088540 · Phase 3 show 10 more results—Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 0%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 0%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 0.3%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination —30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination —10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence —1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | —Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result—Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Serious AEs | 36.8%Cemiplimaba NCT03088540 · Phase 3 show 10 more results27.1%Extended Treatment: Cemiplimab + C NCT03088540 · Phase 3 · combination 35.2%Part 1: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 35.8%Part 1: Cemiplimab+AbbrevChemo+Ipi NCT03409614 · Phase 3 · combination 30.4%Part 2: Cemiplimab + Chemotherapy NCT03409614 · Phase 3 · combination 33.3%30 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 40%20 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 23.8%20 mg/kg in combination with cemiplimab NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 11.1%10 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 25%3 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence 60%1 mg/kg NCT05259696 · Phase 1/2 · registry result, not featured evidence | 40.6%Retifanlimab + Chemotherapy NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more result20.3%Retifanlimab Monotherapy NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
| Most frequent reported AEs | show 10 more resultsanaemia 48.1% (placebo 39.9%) neutropenia 28.7% (placebo 12.4%) alopecia 27.8% (placebo 43.8%) NCT03409614 · Phase 3 · combination anaemia 33.9% (placebo 39.9%) nausea 28.4% (placebo 16.3%) fatigue 21.1% (placebo 8.5%) NCT03409614 · Phase 3 · combination anaemia 44.2% (placebo 39.9%) alopecia 37.5% (placebo 43.8%) nausea 25.3% (placebo 16.3%) NCT03409614 · Phase 3 · combination 30 mg/kg infusion related reaction 66.7% anaemia 33.3% abdominal pain 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg infusion related reaction 66.7% anaemia 40% constipation 26.7% NCT05259696 · Phase 1/2 · registry result, not featured evidence 20 mg/kg in combination with cemiplimab infusion related reaction 42.9% cough 33.3% fatigue 33.3% NCT05259696 · Phase 1/2 · registry result, not featured evidence · combination 10 mg/kg infusion related reaction 55.6% fatigue 33.3% dehydration 22.2% NCT05259696 · Phase 1/2 · registry result, not featured evidence 3 mg/kg abdominal pain 25% arthralgia 25% back pain 25% NCT05259696 · Phase 1/2 · registry result, not featured evidence 1 mg/kg abdominal pain 60% nausea 60% vomiting 40% NCT05259696 · Phase 1/2 · registry result, not featured evidence | anaemia 60.4% (placebo 56.8%) decreased appetite 22.6% (placebo 13.2%) neutrophil count decreased 21.6% (placebo 17.4%) NCT04205812 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 show 1 more resultaspartate aminotransferase increased 23.7% (placebo 22.1%) anaemia 22% (placebo 56.8%) alanine aminotransferase increased 15.3% (placebo 23.7%) NCT04205812 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cemiplimab
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
+ 36 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cemiplimab's landscape · Retifanlimab's landscape